The Profile of Multidrug Tuberculosis Regimen and Treatment Outcomes in Pulmonary MDR-TB Patients at the Tertiary Referral Hospital Dr. Soetomo, East Java, Indonesia: A Seven-Year Retrospective Study on Bedaquiline

Authors

  • Muhamad Frendy Setyawan Doctoral Program of Medical Science, Faculty of Medicine Universitas Airlangga, Surabaya, Indonesia
  • Ni Made Mertaniasih 1. Department of Medical Microbiology, Faculty of Medicine Universitas Airlangga, Surabaya, Indonesia. 2. Dr. Soetomo Hospital, Surabaya, Indonesia. 3. Tuberculosis Laboratory, Institute of Tropical Disease, Universitas Airlangga, Surabaya, Indonesia.
  • Soedarsono Soedarsono 1. Divison of Pulmonology, Department of Internal Medicine, Faculty of Medicine Hang Tuah University, Surabaya, Indonesia. 2. Dr. Soetomo Hospital, Surabaya, Indonesia. 3. Tuberculosis Laboratory, Institute of Tropical Disease, Universitas Airlangga, Surabaya, Indonesia.

Keywords:

drug-resistant tuberculosis, treatment regimen, bedaquiline, WHO guidelines, pulmonary tuberculosis

Abstract

Background: The use of bedaquiline has been reported to minimize the number of lost to follow-up and fewer rejections from the patients. This study is the first to depict the use of bedaquiline. It aims to provide information related to the profile of the MDR-TB drug regimen in the last 7 years with the treatment outcomes of pulmonary MDR-TB patients at a tertiary referral hospital in East Java. Methods: This study was a retrospective, descriptive, and data analysis on 1053 pulmonary MDR-TB patients in tertiary referral hospital Dr Soetomo, East Java, Indonesia, with the SPSS software version 25 and Microsoft Excel 2021. Results: The study analyzed the  MDR-TB treatment regimen following the latest guidelines from WHO (2020) at a tertiary referral hospital in East Java. This study shows that a bedaquiline-containing regimen started in January 2015 to July 2022 with the percentage of distribution (1, 3, 11, 4, 18, 13, 29, 21)% consecutively in the regimen. The treatment outcome profile of MDR-TB patients shows the average percentage of cured (15%), died (12%), lost-to-follow-up cases (27%), moved to an individualized regimen or a different health facility (42%), and currently in the evaluation stage (4%). Overall from January 2017 to July  2022, the number of LTFU cases decreased (42, 46, 29, 19, 8, 4)%. However, the cured case fluctuated between 2017-2022 (16, 28, 26, 32)%  respectively after Bdq started to be included in the regimen regularly for treating RR/MDR-TB. Conclusion: After seven years of study, we revealed an association between adding bedaquiline to the regimen and the treatment success and decreasing lost-to-follow-up cases.

References

Oliveira O, Gaio R, Correia-Neves M, Rito T, Duarte R. Evaluation of drug-resistant tuberculosis treatment outcome in Portugal, 2000–2016. PLoS One. 2021;16(4 April).

Khan I, Ahmad N, Khan S, et al. Evaluation of treatment outcomes and factors associated with unsuccessful outcomes in multidrug resistant tuberculosis patients in Baluchistan province of Pakistan. J Infect Public Health. 2019;12(6):809–15.

Secretary of Jan Swasthya Sahyog, Laux TS, Patil S. Predictors of tuberculosis treatment outcomes among a retrospective cohort in rural, Central India. J Clin Tuberc Other Mycobact Dis. 2018;12:41–7.

El-Shabrawy M, El-Shafei DA. Evaluation of treatment failure outcome and its predictors among pulmonary tuberculosis patients in Sharkia Governorate, 2013–2014. Egyptian Journal of Chest Diseases and Tuberculosis. 2017;66(1):145–52.

Guglielmetti L, Hewison C, Avaliani Z, et al. Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries. International Journal of Tuberculosis and Lung Disease. 2017;21(2):167–74.

Hatami H, Sotgiu G, Bostanghadiri N, et al. Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis. J Bras Pneumol. 2022;48(2):e20210384.

Gao JT, Shu W, Zhang LJ, et al. Prolonged use of bedaquiline in two patients with pulmonary extensively drug-resistant tuberculosis: Two case reports. World J Clin Cases. 2021;9(10):2326–33.

Gao M, Gao J, Xie L, et al. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study. Clinical Microbiology and Infection. 2021;27(4):597–602.

Nahid P, Mase SR, Migliori GB, et al. Treatment of drug-resistant tuberculosis an official ATS/CDC/ERS/IDSA clinical practice guideline. Am J Respir Crit Care Med. 2019;200(10):E93–142.

MR, Padayatchi N, Wolf A, et al. Bedaquiline Adherence Measured by Electronic Dose Monitoring Predicts Clinical Outcomes in the Treatment of Patients With Multidrug-Resistant Tuberculosis and HIV/ AIDS [Internet]. Vol. 90, J Acquir Immune Defic Syndr. 2022. Available from: www.jaids.com|325

Koirala S, Borisov S, Danila E, et al. Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort. Pulmonology. 2021;27(5):403–12.

Fekadu G, Yao J, You JHS. Bedaquiline-based treatment for extensively drug-resistant tuberculosis in South Africa: A cost-effectiveness analysis. PLoS One. 2022;17(8 August).

Khoshnood S, Goudarzi M, Taki E, et al. Bedaquiline: Current status and future perspectives. Journal of Global Antimicrobial Resistance. Elsevier Ltd; 2021;25:48–59.

Mirzayev F, Viney K, Linh NN, et al. World health organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update. European Respiratory Journal. 2021;57.

Putra ON, Damayanti A, Wijayanti N, Nurrahman D, Devi T, Aluf W. Evaluation of category I of anti-tuberculosis therapy in intensive phase pulmonary TB by conversion of acid-fast Bacilli sputum. Original Article Pharmaceutical Sciences and Research (PSR). 2019;6(3):183–8.

Pontali E, Raviglione MC, Migliori GB, et al. Regimens to treat multidrug-resistant tuberculosis: Past, present and future perspectives. European Respiratory Review. 2019;28.

WHO. Rapid communication: Key changes to the treatment of drug-resistant tuberculosis [Internet]. 2022. Available from: https://www.who.int/about/licensing.

Indarti HT, Kristin E, Soedarsono S, Endarti D. Treatment outcomes of multidrug-resistant Tuberculosis patients in East Java, Indonesia: A retrospective cohort analysis. Int J Mycobacteriol. 2022;11(3):261–7.

Giri VP, Giri OP, Pandey PT, et al. The Characteristics and patterns of Drug-Resistant Pulmonary Tuberculosis in Eastern India. Trop Med Infect Dis. 2022;7(9).

Pai H, Ndjeka N, Mbuagbaw L, et al. Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis. BMC Infect Dis. 2022;22(1).

Zhang SJ, Yang Y, Sun WW, et al. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China. BMC Infect Dis. 2022;22(1).

Padmapriyadarsini C, Vohra V, Bhatnagar A, et al. Bedaquiline, Delamanid, Linezolid, and Clofazimine for treatment of pre-extensively drug-resistant Tuberculosis. Clinical Infectious Diseases. 2023;76(3):E938–46.

Hewison C, Khan U, Bastard M, et al. Safety of treatment regimens containing Bedaquiline and Delamanid in the end TB cohort. Clinical Infectious Diseases. 2022;75(6):1006–13.

Kim JH, Lee H, Oh IS, et al. Comparative safety of bedaquiline and delamanid in patients with multidrug resistant tuberculosis: A nationwide retrospective cohort study. Journal of Microbiology, Immunology and Infection. 2023;56(4):842–52.

Zhang SJ, Yang Y, Sun WW, et al. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China. BMC Infect Dis. 2022;22(1).

Traoré AN, Rikhotso MC, Banda NT, et al. Effectiveness of the novel anti-TB Bedaquiline against drug-resistant TB in Africa: A systematic review of the literature. Pathogens. MDP. 2022;11.

Fu L, Weng T, Sun F, et al. Insignificant difference in culture conversion between bedaquiline-containing and bedaquiline-free all-oral short regimens for multidrug-resistant tuberculosis. International Journal of Infectious Diseases. 2021;111:138–47.

World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4, Treatment: drug-resistant tuberculosis treatment. [Internet]. 2020 [cited 2022 Oct 22]. 98 p. Available from: https://apps.who.int/iris/rest/bitstreams/1280998/retrieve

Nunn AJ, Rusen ID, van Deun A, et al. Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): Study protocol for a randomized controlled trial. Trials. 2014;15(1).

Borisov SE, D’Ambrosio L, Centis R, et al. Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery. Journal of Infection. 2019;78(1):35–9.

Koirala S, Borisov S, Danila E, et al. Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort. Pulmonology. 2021;27(5):403–12.

Deshkar AT, Shirure PA. Bedaquiline: A novel diarylquinoline for multidrug-resistant pulmonary Tuberculosis. Cureus. 2022.

Belachew T, Yaheya S, Tilahun N, et al. Multidrug-resistant Tuberculosis treatment outcome and associated factors at the University of Gondar comprehensive specialized hospital: A ten-year retrospective study. Infect Drug Resist. 2022;15:2891–9.

Borisov SE, Dheda K, Enwerem M, et al. Effectiveness and safety of bedaquilinecontaining regimens in the treatment of MDR- and XDR-TB: A multicentre study. European Respiratory Journal. 2017;49(5).

Wang MG, Wu SQ, He JQ. Efficacy of bedaquiline in the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. BMC Infect Dis. 2021;21(1).

Mase S, Chorba T, Parks S, et al. Bedaquiline for the treatment of multidrug-resistant tuberculosis in the United States. Clinical Infectious Diseases. 2020;71(4):1010–6.

Lee T, Lee SJ, Jeon D, et al. Additional drug resistance in patients with multidrug-resistant Tuberculosis in Korea: a multicenter study from 2010 to 2019. J Korean Med Sci. 2021;36(26):1–11.

Ministry of Health and Family Welfare India. Guideline for programmatic multidrug resistant TB in India 2021. Ministry of Health and Family Welfare India [Internet]. 2021 [cited 2022 Dec 16]; Available from: https://tbcindia.gov.in/showfile.php?lid=3590

Downloads

Published

2024-01-12

How to Cite

Setyawan, M. F., Mertaniasih, N. M., & Soedarsono, S. (2024). The Profile of Multidrug Tuberculosis Regimen and Treatment Outcomes in Pulmonary MDR-TB Patients at the Tertiary Referral Hospital Dr. Soetomo, East Java, Indonesia: A Seven-Year Retrospective Study on Bedaquiline. Acta Medica Indonesiana, 55(4), 430. Retrieved from http://www.actamedindones.org/index.php/ijim/article/view/2285

Issue

Vol. 55 No. 4 (2023): Acta Medica Indonesiana

Section

ORIGINAL ARTICLE

License

Copyright

The authors who publish in this journal agree to the following requirements:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a  Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)

Privacy Statement

The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.